CIPRODEX® Otic is easier on wallets

Dollar Icon

EVEN MORE SAVINGS for commercially insured patients

With the CIPRODEX® Otic co-pay card, commercially insured patients can save even more on top of their insurance coverage. In fact, eligible patients may pay as little as $30.*

Co-pay card for patients

Let patients know they can download a co-pay card to use at their pharmacy at

For your patients with
commercial insurance

For co-pay savings: Eligible patients may pay as little as $30*

CIPRODEX® Otic Broad Commercial Coverage

9 out of 10 patients covered1

For your patients with Medicare Part D

CIPRODEX® Otic Broad Medicare Part D Coverage

8 out of 10 patients covered1

For your patients with Medicaid

CIPRODEX® Otic Broad Medicaid Coverage

7 out of 10 patients covered1

Katie Image

Not an actual patient.

Broad commercial, Medicare Part D, and Medicaid coverage

Use the Fingertip Formulary®† to check coverage
Use the Fingertip Formulary®† to check coverage

Not an actual patient.

Visual of Man

*Terms and Conditions: Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program, for cash-paying patients, or where plan reimburses you for the entire cost of your prescription drug. Eligible, commercially insured patients may pay as little as $30 in out-of-pocket expenses for each 7.5mL bottle of CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension with a maximum benefit per bottle of $170. Offer good for up to three (3) 7.5mL bottles of CIPRODEX® Otic for a single patient. If insured patient reaches maximum benefit per bottle, patient will be responsible for the difference. Offer is not valid where prohibited by law. Valid only in the US, USVI, Guam and Puerto Rico. This program is only valid for those patients 6 months and older. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. This card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer.

Fingertip Formulary® is a registered trademark of DR/Decision Resources, LLC.

Plus Icon Plus Icon




Hypersensitivity Reactions: CIPRODEX® Otic should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones.

Potential for Microbial Overgrowth with Prolonged Use: Prolonged use of CIPRODEX® Otic may result in overgrowth of non-susceptible bacteria and fungi. If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.

Continued or Recurrent Otorrhea: If otorrhea persists after a full course of therapy, or if two or more episodes occur within six months, further evaluation is recommended to exclude an underlying condition such as cholesteatoma, foreign body, or a tumor.


The most commonly reported adverse reactions in clinical trials were:


CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in:


For additional information on CIPRODEX® Otic, please click here for the full Prescribing Information.

References: 1. Alcon Fingertip Formulary. Burlington, MA: Decision Resources LLC; 2017. Accessed May 25, 2017.